This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Stock Reports for Apple, Exxon Mobil & AT&T
by Mark Vickery
. Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Exxon Mobil (XOM) and AT&T (T).
Why Is Cardinal (CAH) Up 3.5% Since Last Earnings Report?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
Can Value Investors Consider Cardinal Health (CAH) Stock?
by Zacks Equity Research
Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.
Company News For Aug 9, 2019
by Zacks Equity Research
Companies in the news are: CAH, KTB, NCLH and VIAB
Cardinal Health (CAH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health (CAH) Q4 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, contraction in gross margin remains a concern.
Cardinal Health (CAH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 19.35% and 1.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical and Medical segments are likely to aid Cardinal Health's (CAH) in Q4 earnings.
Analysts Estimate Cardinal Health (CAH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Cardinal Health, Builders FirstSource, AmerisourceBergen, AutoNation and Party City
by Zacks Equity Research
Zacks.com featured highlights include: Cardinal Health, Builders FirstSource, AmerisourceBergen, AutoNation and Party City
Recent Analyst Upgrades Add Shine to These 5 Stocks
by Maharathi Basu
The opinion of brokers is highly valued by investors as they have a clear insight into the nitty gritty of the investment world.
Zacks.com featured highlights include: Antero Resources, Avis Budget, NOW, Cardinal Health and Asbury Automotive
by Zacks Equity Research
Zacks.com featured highlights include: Antero Resources, Avis Budget, NOW, Cardinal Health and Asbury Automotive
5 Broker-Favorite Stocks to Watch Out For
by Maharathi Basu
The task of designing one's portfolio to include potential outperformers is anything but easy. Broker advice helps to design a winning portfolio.
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Retain Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
Why Is Cardinal (CAH) Down 12.5% Since Last Earnings Report?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News For May 10, 2019
by Zacks Equity Research
Companies In The News Are: TPR,ROKU,AMC,CAH
Cardinal Health (CAH) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Cardinal Health (CAH) Q3 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, sluggishness in the Medical segment remains a concern.
Cardinal Health (CAH) Q3 Earnings Top Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 11.19% and -0.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Cardinal Health (CAH) Might Surprise This Earnings Season
by Zacks Equity Research
Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Inogen (INGN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Inogen's (INGN) first-quarter 2019 results are expected to get a boost from product launches.
Cardinal Health (CAH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed at $49.50 in the latest trading session, marking a +1.56% move from the prior day.
Can Cardinal (CAH) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) expects BD Medical to drive fiscal Q2 results; foreign exchange headwinds persist.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.